Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Interest & Investment Income (2022 - 2025)

Stoke Therapeutics has reported Interest & Investment Income over the past 4 years, most recently at $3.6 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 21.72% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $13.8 million, up 8.86%, while the annual FY2025 figure was $13.8 million, 8.85% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $3.6 million at Stoke Therapeutics, up from $3.5 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $3.8 million in Q2 2025 and troughed at $104000.0 in Q1 2022.
  • A 4-year average of $2.5 million and a median of $2.6 million in 2023 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: surged 1922.12% in 2023 and later dropped 2.31% in 2025.
  • Year by year, Interest & Investment Income stood at $1.5 million in 2022, then skyrocketed by 74.92% to $2.6 million in 2023, then rose by 14.8% to $3.0 million in 2024, then rose by 21.72% to $3.6 million in 2025.
  • Business Quant data shows Interest & Investment Income for STOK at $3.6 million in Q4 2025, $3.5 million in Q3 2025, and $3.8 million in Q2 2025.